Switch to Dawn Waterhouse's research page...

2009

1. Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K, Bally M. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res. 11(3):R25. (2009).
    [View Abstract - PubMed 19409087]  Request Paper

2008

2. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB . Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70. (2008).
    [View Abstract - PubMed 18202010]  Request Paper

3. Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D and Bally M. A Novel Liposomal Irinotecan Formulation with Significant Anti-tumor Activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention Eur J Pharm 2008 Mar;68(3):607-17. Epub 2007 Sept 2 (2008).
    [View Abstract - PubMed 17904831]  Request Paper

4. Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, Strutt D, Webb MS, Waterhouse D and Bally MB (2008). Irinophore C^TM : A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy Against a Panel of Human Xenograft Tumors Clin Cancer Res. 2008;14(4):1208-17 (2008).
    [View Abstract - PubMed 18281556]  Request Paper

5. de Lemos ML, Monfared S, Denyssevych T, Hamata L, Jennings S, Thiessen B, Smith S, Waterhouse D. Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer's solution for intrathecal administration. J Oncol Pharm Pract. 2008 Sep 4. [Epub ahead of print] (2008).
    [View Abstract - PubMed 18772215]  Request Paper

2007

6. Chiu GN, Edwards LA, Kapanen AI, Malinen MM, Dragowska WH, Warburton C, Chikh GG, Fang KY, Tan S, Sy J, Tucker C, Waterhouse DN, Klasa R, Bally MB. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther. 6(3):844-55. Epub 2007 Mar 5. (2007).
    [View Abstract - PubMed 17339368]  Request Paper

2006

7. Chui GNC, Harasym TO, Tardi PG, Bally MB and Waterhouse D. Optimization and Therapeutic Activity of Liposome-Conjugated Monoclonal Antibodies Against theErbB Family of Receptor Tyrosine Kinases: First Step in the Development of Therapeutic Antibody/Liposomal Anticancer Drug Combinations Letters in Drug Design and Discovery (2006).
    Request Paper

8. Cogswell S, Berger S, Waterhouse D, Bally MB, Wasan EK. A parenteral econazole formulation using a novel micelle-to-liposome transfer method: in vitro characterization and tumor growth delay in a breast cancer xenograft model. Pharm Res. 23(11):2575-85. Epub 2006 Sep 13. (2006).
    [View Abstract - PubMed 17086505]  Request Paper

9. Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets. 6(6):455-89. (2006).
    [View Abstract - PubMed 17017873]  Request Paper

2005

10. Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J Control Release. 105(1-2):89-105. (2005).
     [View Abstract - PubMed 15878792]  Request Paper

11. Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Pharm Res. 22(6):915-22. Epub 2005 Jun 8. (2005).
     [View Abstract - PubMed 15948035]  Request Paper

2004

12. Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization. Mol Cancer Res. 2(11):606-19. (2004).
     [View Abstract - PubMed 15561777]  Request Paper

13. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res. 10(19):6638-49. (2004).
     [View Abstract - PubMed 15475454]  Request Paper

14. Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model. Cancer Biol Ther 3(2):197-204. Epub 2004 Feb. (2004).
     [View Abstract - PubMed 14726684]  Request Paper

2003

15. Waterhouse DN, Gelmon KA, Masin D, Bally MB. Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. J Exp Ther Oncol 3(5):261-71. (2003).
     [View Abstract - PubMed 14696623]  Request Paper

2002

16. Wasan EK, Waterhouse D, Sivak O, Bally MB, Klasa RJ, Wasan KM. Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. Int J Pharm 241(1):57-64. (2002).
     [View Abstract - PubMed 12086721]  Request Paper

2001

17. Waterhouse DN, Dos Santos N, Mayer LD, Bally MB. Drug-Drug Interactions Arising From The Use Of Liposomal Vincristine In Combination With Other Anti-Cancer Drugs Pharm. Res. Sep;18(9):1331-5 (2001).
     [View Abstract - PubMed 11683249]  Request Paper

18. Waterhouse DN, Dragowska VH, Gelmon KA, Mayer LD, Bally MB . Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor as Measured in an Ascitic MDA435/LCC6 Human Breast Cancer Model JPET (Submitted) (2001).
     Request Paper

19. Waterhouse DN, Gelmon KA, Masin D, Bally MB. In Vivo Treatment of Human Breast Carcinoma Xenografts with a Liposomal Formulation of Anti-HER-2/neu Antisense Oligodeoxynucleotides Clin Cancer Res (Submitted) (2001).
     Request Paper

20. Waterhouse DN, Tardi PG, Mayer LD, Bally MB. Changing Toxicity Profiles: A Comparison Of Liposomal Formulations Of Doxorubicin To Drug Administered In Free Form Drug Safety (In Press) (2001).
     Request Paper

1999

21. Saxon DN, Mayer LD, Bally MB. Liposomal anticancer drugs as agents to be used in combination with other anticancer agents: Studies on a liposomal formulation with two encapsulated drugs J Liposome Res. 9(4) p.507-522 (1999).
     Request Paper

1998

22. Webb MS, Boman NL, Wiseman DJ, Saxon D, Sutton K, Wong KF, Logan P, Hope MJ. Antibacterial Efficacy Against an In Vivo Salmonella typhimurium Infection Model and Pharmacokinetics of a Liposomal Ciprofloxacin Formulation Antimicrobial Agents and Chemotherapy, 42(1), 45-52 (1998).
     [View Abstract - PubMed 9449259]  Request Paper

23. Webb MS, Saxon D, Wong FMP. Lim H, Bally MB, Choi LSL, Cullis PR, Mayer LD. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine Biochim Biophys Acta 17;1372(2) p.272-82 (1998).
     [View Abstract - PubMed 9675310]  Request Paper

2009

1. Waterhouse D. Therapeutic potential of siRNA: building on lessons learned from cytotoxic and oligonucleotide delivery strategies: part III Nanomedicine 2009; 4(2), 132-133. (2009).
    Request Paper

2. Waterhouse D . Mechanistic studies of Irinophore CTM lead to discovery of enhanced delivery of co-administered drugs Nanomedicine 2009; 4(2), 129-130. (2009).
    Request Paper

3. Waterhouse D . Therapeutic potential of siRNA: building on lessons learned from cytotoxic and oligonucleotide delivery strategies: part II Nanomedicine 2009; 4(2), 131-132. (2009).
    Request Paper

4. Waterhouse D . Therapeutic potential of siRNA: building on lessons learned from cytotoxic and oligonucleotide delivery strategies: part I Nanomedicine 2009; 4(2), 130-131. (2009).
    Request Paper

2000

5. Saxon DN, Chia SK, Bally MB . Drug Combinations for Therapy of Aggressive Breast Cancer: Antisense Oligonucleotides Against HER-2/neu Physicians Education Resource; HER2 in Oncology Vol. 1 No. 3 (2000).
    Request Paper

6. Waterhouse D. Therapeutic potential of siRNA: building on lessons learned from cytotoxic and oligonucleotide delivery strategies: part II Nanomedicine 2009; 4(2), 131-132. ().
    Request Paper

7. Waterhouse D. Therapeutic potential of siRNA: building on lessons learned from cytotoxic and oligonucleotide delivery strategies: part II Nanomedicine 2009; 4(2), 131-132. ().
    Request Paper

8. Waterhouse D. Therapeutic potential of siRNA: building on lessons learned from cytotoxic and oligonucleotide delivery strategies: part II Nanomedicine 2009; 4(2), 131-132. ().
    Request Paper

2008

1. Waterhouse DN, Kalra J, Verreault M, Ramsay E, Dragowska W, Yapp D, Webb M, Chiu G and Bally MB . Nanotechnology as an Enabling Approach to the Development of Fixed-Dose Combination Products for Treating Cancer In: Handbook of Particulate Drug Delivery, Vol.2: Applications, pp.11-39 (M.N.V. Ravi Kumar, Ed), American Scientific Publishers (2008).
    Request Paper

2005

2. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 391:71-97. (2005).
    [View Abstract - PubMed 15721375]  Request Paper

3. Waterhouse DN, Madden TD, Cullis PR, Bally MB, Mayer LD, Webb MS. Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods Enzymol. 391:40-57. (2005).
    [View Abstract - PubMed 15721373]  Request Paper

2000

1. Saxon DN, Masin D, Mayer LD, Bally MB. In vivo treatment of human breast carcinoma xenografts with anti-HER-2/neu antisense oligonucleotides 7th Liposome Research Days. (2000).
    Request Paper

2001

1. Saxon, DN, Gelmon, KA, Mayer, LD and Bally, MB. Anti-HER-2/neu antisense olgonucleotides in the treatment of MDA435/LCC6 ascites tumours Proc. Amer. Assoc. for Cancer Res. 42 (2001).
    Request Paper

2000

2. Chia SKL, Gelmon K, Saxon D, Bally M. Comparative efficacy of an anti-sense oligonucleotide to HER-2/neu in combination with tamoxifen versus Herceptin and tamoxifen in HER-2/neu overexpressing human breast tumor cell lines Proc. Amer. Assoc. for Cancer Res. 41, p. 389 (2000).
    Request Paper

3. Sivak O, Wasan EK, Bally M, Saxon D, Wasan KM. Plasma protein binding and lipoprotein distribution of Bcl-2 antisense oligodeoxynucleotides (AO) Proc. Amer. Assoc. of Pharm Sci. (2000).
    Request Paper

1999

4. Saxon DN, Lutwyche P, Webb M, Bally MB. Downregulation of HER-2/neu by an anti-HER-2/neu phosphorothioate oligonucleotide and its use in combination with doxorubicin for treatment of breast cancer xenograft models Proc. Amer. Assoc. for Cancer Res. 40, p. 480 (1999).
    Request Paper